Genomic Vision Stock

Genomic Vision FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Genomic Vision (GV.PA) as of Sep 9, 2026 is 66.45 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 92.38 % — a change of -28.07% (lower).

FCF Conversion

66.45 %

YoY

-28.07%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Genomic Vision is 2026 66.45 % . FCF Conversion Rate (FCF/EBITDA) of Genomic Vision was 2025 92.38 % . It decreases by -28.07% lower compared to the previous year.

The Genomic Vision FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
163.07 EUR
Jan 1, 2016
100.98 EUR
Jan 1, 2017
90.43 EUR
Jan 1, 2018
82.01 EUR
Jan 1, 2019
111.50 EUR
Jan 1, 2020
73.58 EUR
Jan 1, 2021
92.38 EUR
Jan 1, 2022
66.45 EUR
The Genomic Vision FCF Conversion history
YEARFCF ConversionYoY
66.45 %-28.07%
92.38 %+25.55%
73.58 %-34.01%
111.50 %+35.96%
82.01 %-9.31%
90.43 %-10.44%
100.98 %-38.08%
163.07 %-16.53%
195.36 %—
Access this data via the Eulerpool API
Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

FCF Conversion Rate (FCF/EBITDA) of Genomic Vision is 66.45 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Genomic Vision changed from 92.38 % to 66.45 %, representing a -28.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Genomic Vision with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Genomic Vision

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Genomic Vision